Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edesa Biotech Inc EDSA

Healthcare Biotechnology
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a... see more

Recent & Breaking News (NDAQ:EDSA)

Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study

Accesswire July 25, 2019

Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study

Canada NewsWire June 20, 2019

Edesa Biotech and Stellar Biotechnologies Complete Business Combination

Canada NewsWire June 7, 2019

Stellar Biotechnologies Reports Second Quarter Financial Results

PR Newswire May 8, 2019

Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement

PR Newswire March 8, 2019

Stellar Biotechnologies Reports First Quarter Financial Results

PR Newswire February 5, 2019

Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results

PR Newswire November 30, 2018

Detailed Research: Economic Perspectives on Stellar Biotechnologies, MAM Software Group, EverQuote, Brainstorm Cell Therapeutics, Mid-Con Energy Partners, LP, and Staffing 360 Solutions — What Drives Growth in Today's Competitive Landscape

GlobeNewswire November 21, 2018

Stellar Biotechnologies to Present at BlueTech Summit

PR Newswire October 31, 2018

Stellar Biotechnologies to Supply KLH to National Institutes of Health

PR Newswire September 5, 2018

Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference

PR Newswire August 28, 2018

Stellar Biotechnologies Reports Third Quarter Financial Results

PR Newswire August 8, 2018

Stellar Issues Statement on Favorable Clinical Study Results

PR Newswire July 5, 2018

Stellar Reports Positive Research Results from KLH Glycosylation Study

PR Newswire June 21, 2018

Stellar Biotechnologies Announces Exercise of Warrants Resulting in Cash Proceeds of $3 Million

PR Newswire May 24, 2018

Mid-Day Market Update: Westell Drops Following Weak Q4 Earnings; Destination Maternity Shares Climb

Benzinga.com  May 24, 2018

Mid-Morning Market Update: Markets Open Lower; McKesson Earnings Miss Estimates

Benzinga.com  May 24, 2018

Stellar Achieves Robust Viral Clearance for Manufacturing Process

PR Newswire May 24, 2018

Stellar Biotechnologies Announces Closing of $5.5 Million Public Offering

PR Newswire May 15, 2018

Mid-Day Market Update: Trade Desk Surges on Upbeat Earnings; Stellar Biotechnologies Shares Drop

Benzinga.com  May 11, 2018